Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Simon Heidegger

Showing results (1-10 of 36) with videos related to

Pageof 4
Sort By:
Immunity|March 23, 2017
Cutting Edge in IFN Regulation: Inflammatory Caspases Cleave cGASSimon Heidegger, Tobias Haas, Hendrik Poeck
Hematology/Oncology Clinics of North America|March 6, 2019
Innate Immune Stimulation in Cancer TherapyPeter Düwell, Simon Heidegger, Sebastian Kobold
Journal of Visualized Experiments : Jove|October 11, 2021
In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T CellsFlorian Stritzke, Hendrik Poeck, Simon Heidegger
European Journal of Immunology|March 18, 2021
Tumor cell-intrinsic RIG-I signaling governs synergistic effects of immunogenic cancer therapies and checkpoint inhibitors in miceHendrik Poeck, Alexander Wintges, Sarah Dahl, et al.
Plos One|November 14, 2015
Mycoplasma hyorhinis-Contaminated Cell Lines Activate Primary Innate Immune Cells via a Protease-Sensitive FactorSimon Heidegger, Alexander Jarosch, Martina Schmickl, et al.
Frontiers in Immunology|August 8, 2014
The role of pattern-recognition receptors in graft-versus-host disease and graft-versus-leukemia after allogeneic stem cell transplantationSimon Heidegger, Marcel R M van den Brink, Tobias Haas, et al.
Molecular Therapy Oncolytics|September 1, 2023
Oncolytic virotherapy with chimeric VSV-NDV synergistically supports RIG-I-dependent checkpoint inhibitor immunotherapyJanina Marek, Lorenz Hanesch, Teresa Krabbe, et al.
Oncotargets and Therapy|July 15, 2014
Combination therapy with brentuximab vedotin and cisplatin/cytarabine in a patient with primarily refractory anaplastic lymphoma kinase positive anaplastic large cell lymphomaSimon Heidegger, Ambros J Beer, Eva Geissinger, et al.
Nanoscale|December 15, 2015
Immune response to functionalized mesoporous silica nanoparticles for targeted drug deliverySimon Heidegger, Dorothée Gössl, Alexandra Schmidt, et al.
ACS Nano|November 19, 2011
Cellular immunostimulation by CpG-sequence-coated DNA origami structuresVerena J Schüller, Simon Heidegger, Nadja Sandholzer, et al.
Pageof 4

Showing results (1-10 of 36) with videos related to

Sort By:
Pageof 4
Immunity|March 23, 2017
Cutting Edge in IFN Regulation: Inflammatory Caspases Cleave cGASSimon Heidegger, Tobias Haas, Hendrik Poeck
Hematology/Oncology Clinics of North America|March 6, 2019
Innate Immune Stimulation in Cancer TherapyPeter Düwell, Simon Heidegger, Sebastian Kobold
Journal of Visualized Experiments : Jove|October 11, 2021
In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T CellsFlorian Stritzke, Hendrik Poeck, Simon Heidegger
European Journal of Immunology|March 18, 2021
Tumor cell-intrinsic RIG-I signaling governs synergistic effects of immunogenic cancer therapies and checkpoint inhibitors in miceHendrik Poeck, Alexander Wintges, Sarah Dahl, et al.
Plos One|November 14, 2015
Mycoplasma hyorhinis-Contaminated Cell Lines Activate Primary Innate Immune Cells via a Protease-Sensitive FactorSimon Heidegger, Alexander Jarosch, Martina Schmickl, et al.
Frontiers in Immunology|August 8, 2014
The role of pattern-recognition receptors in graft-versus-host disease and graft-versus-leukemia after allogeneic stem cell transplantationSimon Heidegger, Marcel R M van den Brink, Tobias Haas, et al.
Molecular Therapy Oncolytics|September 1, 2023
Oncolytic virotherapy with chimeric VSV-NDV synergistically supports RIG-I-dependent checkpoint inhibitor immunotherapyJanina Marek, Lorenz Hanesch, Teresa Krabbe, et al.
Oncotargets and Therapy|July 15, 2014
Combination therapy with brentuximab vedotin and cisplatin/cytarabine in a patient with primarily refractory anaplastic lymphoma kinase positive anaplastic large cell lymphomaSimon Heidegger, Ambros J Beer, Eva Geissinger, et al.
Nanoscale|December 15, 2015
Immune response to functionalized mesoporous silica nanoparticles for targeted drug deliverySimon Heidegger, Dorothée Gössl, Alexandra Schmidt, et al.
ACS Nano|November 19, 2011
Cellular immunostimulation by CpG-sequence-coated DNA origami structuresVerena J Schüller, Simon Heidegger, Nadja Sandholzer, et al.
Pageof 4